Merus NV (Merus NV) 12-1 Month Momentum % : 134.78% (As of May. 01, 2024)

View and export this data going back to 2016. Start your Free Trial

What is Merus NV 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-05-01), Merus NV's 12-1 Month Momentum % is 134.78%.

The industry rank for Merus NV's 12-1 Month Momentum % or its related term are showing as below:

MRUS's 12-1 Month Momentum % is ranked better than
93.44% of 1478 companies
in the Biotechnology industry
Industry Median: -20.535 vs MRUS: 134.78

Competitive Comparison of Merus NV's 12-1 Month Momentum %

For the Biotechnology subindustry, Merus NV's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Merus NV's 12-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Merus NV's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Merus NV's 12-1 Month Momentum % falls into.

Merus NV (NAS:MRUS) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %

( Price 1-month ago

Price 12-month ago

- 1 )

100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Merus NV (NAS:MRUS) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Merus NV 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Merus NV's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.

Merus NV (Merus NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Merus NV (NAS:MRUS) » Definitions » 12-1 Month Momentum %

Comparable Companies

Traded in Other Exchanges

2GH:Germany

Address

Uppsalalaan 17, Utrecht, NLD, 3584 CT

Website

https://www.merus.nl

Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.

Executives

Harry Shuman	officer: Chief Accounting Officer	C/O MERUS N.V., VALELAAN 62, UTRECHT P7 3584 CM
Peter B. Silverman	officer: EVP & General Counsel	C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584 CM
Sven Ante Lundberg	director, officer: President, CEO & PFO	C/O CRISPR THERAPEUTICS AG, 200 SIDNEY STREET, CAMBRIDGE MA 02139
Biotechnology Value Fund L P	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Kruif John De	officer: Chief Technology Officer	C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584 CM
Paolo Pucci	director	C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Len Kanavy	director	C/O MERUS N.V., VALELAAN 62, UTRECHT P7 3584 CM
Maxine Gowen	director
Anand Mehra	director	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Victor Sandor	director	C/O ARRAY BIOPHARMA INC., 3200 WALNUT STREET, BOULDER CO 80301
Mark T Iwicki	director	84 WATERFORD DRIVE, MARLBOROUGH MA 01752
Gregory D Perry	director	C/O IMMUNOGEN, INC., 830 WINTER ST., WALTHAM MA 02451
Geuijen Cecile A W	officer: SVP & Chief Scientific Officer	C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584CM
Andrew Joe	officer: SVP, CMO	C/O MERUS N.V., VALELAAN 62, UTRECHT P7 3584 CM
Mark Throsby	officer: EVP & Chief Scientific Officer	C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584 CM